Back to Authors

Jawad, Majd D

Mayo Clinic

Division of Hematology Mayo Clinic Rochester Minnesota.

Citations 2

Clinical course of patients with incidental finding of 20q‐ in the bone marrow without a morphologic evidence of myeloid neoplasm
Jawad, Majd, Oliveira, Jennifer L. , Hoyer, James D., Hook, C. Christopher , Herrick, Jennifer L. , Jawad, Majd D, Shi, Min , Go, Ronald S.

American Journal of Hematology | March 1, 2016 | Volume: 91 | Issue: 6 | Pages: 556-559

10.1002/ajh.24347 Get It

Deletion of the long arm of chromosome 20 (20q‐) is a frequent finding in bone marrow karyotypes, mainly associated with myeloid neoplasms (MNs). Its clinical significance in the setting of normal bone marrow morphology is unclear. We described the clinical characteristics, cytogenetic findings, and outcome of 102 such patients seen at our institution from 2000‐2014. Their median age was 66 years. The indication for bone marrow biopsy was either unexplained cytopenias (48%) or hematologic cancer staging/reevaluation (52%). In 88 (86%) patients, 20q‐ was an isolated finding. Thirty‐nine (38%) patients previously received chemotherapy and 88 (86%) had cytopenias at the time of 20q‐ finding. After a median of 35 months, 12 (13%) patients developed MNs: 10 myelodysplastic syndromes, one acute myeloid leukemia and one myeloproliferative neoplasm. None of 14 patients with normal blood counts, but 7 of 35 (20%) with mild cytopenias, and 5 of 53 (9%) with moderate/severe cytopenias developed MNs. We did not find an association between the number of metaphases with 20q‐ and the development of MN. The incidental finding of 20q‐ in the bone marrow generally does not portend an early stage MN. Particularly, those without cytopenias at the time of diagnosis may have a good prognosis. Am. J. Hematol. 91:556–559, 2016. © 2016 Wiley Periodicals, Inc.
Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report
Jawad, Majd, Begna, Kebede H. , Reichard, Kaaren K. , Jawad, Majd D, Go, Ronald S. , Ketterling, Rhett P. , Shi, Min

Clinical Case Reports | February 8, 2016 | Volume: 4 | Issue: 3 | Pages: 282-286

10.1002/ccr3.506 Get It

Key Clinical MessageTyrosine kinase inhibitor treated chronic myelogenous leukemia patients with monosomy 7 arising in Philadelphia chromosome negative (Ph−) cells tend to evolve into MDS/AML. However, monosomy 7 in Ph− cells can be a transient finding, and it is not an absolute indication of the emergence of a new myeloid malignancy.